Journal ArticleDOI
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.
Roham T. Zamanian,David B. Badesch,Lorinda Chung,Robyn T. Domsic,Thomas A. Medsger,Ashley Pinckney,Lynette Keyes-Elstein,Carla D’Aveta,Meagan Spychala,R. James White,Paul M. Hassoun,Fernando Torres,Andrew J. Sweatt,Jerry A. Molitor,Dinesh Khanna,Holden Maecker,Beverly Welch,Ellen Goldmuntz,Mark R. Nicolls,Mark R. Nicolls +19 more
Reads0
Chats0
TLDR
In this paper, the authors investigated the role of B cells in SSc pathogenesis and found that B cells may contribute to the pathogenesis of SSc and pulmonary arterial hypertension (PAH).Abstract:
Rationale: Systemic sclerosis (SSc)–pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis. Objectives: We investigat...read more
Citations
More filters
Journal ArticleDOI
Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
Bradley A. Maron,Steven H. Abman,C. Greg Elliott,Robert P. Frantz,Rachel K. Hopper,Evelyn M. Horn,Mark R. Nicolls,Oksana A. Shlobin,Sanjiv J. Shah,Gabor Kovacs,Horst Olschewski,Erika B. Rosenzweig +11 more
TL;DR: The diagnosis and management of pulmonary arterial hypertension (PAH) includes several advances, such as a broader recognition of extrapulmonary vascular organ system involvement, validated point-of-care clinical assessment tools, and focus on the early initiation of multiple pharmacotherapeutics in appropriate patients as mentioned in this paper.
Journal ArticleDOI
Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells
TL;DR: The concept of targeting B cells as part of the therapeutic plan for SSc through well designed clinical trials is supported through welldesigned clinical trials.
Journal ArticleDOI
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
Hideyuki Ujiie,David H. Rosmarin,Michael P. Schön,Sonja Ständer,Katharina Boch,Martin Metz,Marcus Maurer,Diamant Thaçi,R. Schmidt,C. Cole,Kyle T. Amber,Dario Didona,Michael Hertl,Andreas Recke,Hanna Grasshoff,Alexander Hackel,Anja Schumann,Gabriela Riemekasten,Katja Bieber,Gant Sprow,Joshua Dan,Detlef Zillikens,Tanya Sezin,Angela M. Christiano,Kerstin Wolk,Robert Sabat,Khalaf Kridin,Victoria P. Werth,Ralf Ludwig +28 more
TL;DR: A significant improvement in diagnosis and treatment of chronic inflammatory skin diseases is seen, but several challenges remain, including insufficient therapeutic responses and relapses.
Journal ArticleDOI
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine
TL;DR: In this paper, a review discusses the rationale, preclinical evidence, first clinical e-evidence, and pending issues concerning new promising therapeutic options that are under investigation in SSc.
Journal ArticleDOI
Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension: Implications for Therapy.
Benoit Lechartier,Nihel Berrebeh,Nihel Berrebeh,Alice Huertas,Alice Huertas,Marc Humbert,Marc Humbert,Christophe Guignabert,Christophe Guignabert,Ly Tu,Ly Tu +10 more
TL;DR: In this paper, the medial and non-medial origins of contractile cells in the pulmonary vascular wall and evidence of how they contribute to the onset and progression of pulmonary arterial hypertension is presented.
References
More filters
Journal ArticleDOI
Naturally Arising CD4+ Regulatory T Cells for Immunologic Self-Tolerance and Negative Control of Immune Responses
TL;DR: How naturally arising CD25+CD4+ regulatory T cells contribute to the maintenance of immunologic self-tolerance and negative control of various immune responses, and how they can be exploited to prevent and treat autoimmune disease, allergy, cancer, and chronic infection, or establish donor-specific transplantation tolerance are discussed.
Journal ArticleDOI
Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry
Gilbert E. D'Alonzo,Robyn J. Barst,Stephen M. Ayres,Edward H. Bergofsky,Bruce H. Brundage,Katherine M. Detre,Alfred P. Fishman,Roberta M. Goldring,Berton M. Groves,Janet T. Kernis,Paul S. Levy,Giuseppe G. Pietra,Lynne Reid,John T. Reeves,Stuart Rich,Carol E. Vreim,George W. Williams,Margaret Wu +17 more
TL;DR: Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index.
Journal ArticleDOI
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin,Antonio J. Grillo-Lopez,Brian K. Link,Ronald Levy,Myron S. Czuczman,Michael E. Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vinay K. Jain,A D Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
TL;DR: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Journal ArticleDOI
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Jonathan C. W. Edwards,Leszek Szczepanski,Jacek Szechiński,Anna Filipowicz-Sosnowska,Paul Emery,D. Close,Randall M Stevens,T. Shaw +7 more
TL;DR: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotRexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Journal ArticleDOI
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff Mitchell E,Kristin Carner,Karen S. Chambers,Paul Chinn,John E Leonard,Ron Raab,Roland A. Newman,Nabil Hanna,Darrell R Anderson +8 more
TL;DR: In vitro studies showed the ability of C2B8 to bind human C1q, mediate complement-dependent cell lysis of human B-lymphoid cell lines, and lyse human target cells through antibody-dependent cellular cytotoxicity and the possibility of using an "immunologically active" chimeric anti-CD20 antibody as an alternative approach in the treatment of B-cell lymphoma.
Related Papers (5)
The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis.
Michael H. Lee,Todd M. Bull +1 more